The Death of the Strategy of Classical Chiral Switches Is an Exaggeration

The strategy of classical chiral switches of drugs is still alive, contrary to a 2024 <i>Journal of Medicinal Chemistry</i> Perspective on approved chiral drugs claiming its death. Surveys of approved chiral-switch and racemic drugs should be based on reports of global regulatory authorities, not just FDA and EMA, which revealed overlooked chiral switches and racemates. The approved antihypertensive racemate nebivolol indicates the synergy between its enantiomers, highlighting the advocacy of developing racemic drugs.